Ocugen (OCGN) Change in Accured Expenses (2014 - 2026)
Ocugen (OCGN) posted Change in Accured Expenses of -$5.4 million for Q1 2026, down 547.6% on a QoQ basis from $1.2 million in Q4 2025, and down 65.18% year-over-year from -$15.5 million in Q1 2025.
Ocugen (OCGN) Change in Accured Expenses (2014 - 2026) Analysis & Trends
Ocugen's Change in Accured Expenses history runs 13 years deep, the most recent figure standing at -$5.4 million for Q1 2026.
- Quarterly Change in Accured Expenses fell 65.18% year-over-year to -$5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 48.98% YoY) and the FY2025 annual result came in at $3.3 million, down 19.97% from the prior year.
- Change in Accured Expenses was -$5.4 million for Q1 2026 at Ocugen, down from $1.2 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $3.9 million in Q3 2022 and bottomed at -$5.4 million in Q1 2026.
- A 5-year average of -$47411.8 and a median of $1.2 million in 2025 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 380.45% — and 2023, when it plunged 3889.31%.
- Ocugen's Change in Accured Expenses stood at $2.8 million in 2022, then plunged by 170.5% to -$1.9 million in 2023, then surged by 207.62% to $2.1 million in 2024, then plunged by 42.27% to $1.2 million in 2025, then slumped by 547.6% to -$5.4 million in 2026.
- Business Quant data shows OCGN's Change in Accured Expenses at -$5.4 million in Q1 2026, $1.2 million in Q4 2025, and $3.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,899.87 Bn | 1,899.81 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 470.43 Bn | 465.64 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 123.43 Bn | 116.19 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 70.20 Bn | 61.44 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 61.75 Bn | 61.75 Bn | - | - |
| 8 | Argenx Se | 56.15 Bn | 50.96 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Ocugen | 411.07 Mn | 411.07 Mn | - | -5.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.40 Mn |
| Mar 31, 2026 | -5.40 Mn |
| Dec 31, 2025 | 1.21 Mn |
| Dec 31, 2025 | 1.21 Mn |
| Sep 30, 2025 | 3.29 Mn |
| Sep 30, 2025 | 3.29 Mn |
| Jun 30, 2025 | 2.08 Mn |
| Jun 30, 2025 | 2.08 Mn |
| Mar 31, 2025 | -3.27 Mn |
| Mar 31, 2025 | -3.27 Mn |
| Dec 31, 2024 | 2.09 Mn |
| Dec 31, 2024 | 2.09 Mn |
| Sep 30, 2024 | 2.16 Mn |
| Sep 30, 2024 | 2.16 Mn |
| Jun 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 1.33 Mn |
| Mar 31, 2024 | -1.45 Mn |
| Mar 31, 2024 | -1.45 Mn |
| Dec 31, 2023 | -1.94 Mn |
| Dec 31, 2023 | -1.94 Mn |